Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19021929 | LEVODOPA DOSING REGIMEN | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19022531 | LEVODOPA DOSING REGIMEN | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19022122 | LEVODOPA DOSING REGIMEN | January 2025 | April 2025 | Allow | 3 | 1 | 0 | No | No |
| 19021696 | LEVODOPA DOSING REGIMEN | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19022256 | LEVODOPA DOSING REGIMEN | January 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 19009519 | Compositions and Methods for Treating CNS Disorders | January 2025 | November 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18934978 | PHARMACEUTICAL COMPOSITIONS | November 2024 | April 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18904150 | DELAYED RELEASE ORAL PHARMACEUTICAL COMPOSITION | October 2024 | October 2025 | Allow | 12 | 2 | 0 | No | No |
| 18823153 | LEVODOPA DOSING REGIMEN | September 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18823575 | LEVODOPA DOSING REGIMEN | September 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18817743 | LEVODOPA DOSING REGIMEN | August 2024 | February 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18802458 | LEVODOPA DOSING REGIMEN | August 2024 | February 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18802151 | LEVODOPA DOSING REGIMEN | August 2024 | April 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18751870 | INHALABLE HORMONE RECEPTOR AGONIST FORMULATIONS | June 2024 | July 2025 | Abandon | 13 | 1 | 1 | No | No |
| 18731605 | LEVODOPA DOSAGE FORM | June 2024 | January 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18634040 | LEVODOPA DOSING REGIMEN | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18592672 | SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES | March 2024 | July 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18438675 | Compositions and Methods for Treating CNS Disorders | February 2024 | December 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18419883 | LIQUID CLONIDINE EXTENDED RELEASE COMPOSITION | January 2024 | November 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18416289 | PHARMACEUTICAL DOSAGE FORMS | January 2024 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18397827 | Solid Dosage Form | December 2023 | August 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18392602 | NEW PHARMACEUTICAL COMPOSITIONS | December 2023 | October 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18392666 | NEW PHARMACEUTICAL COMPOSITIONS | December 2023 | October 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18535139 | DEVICES, KITS AND METHODS FOR REDUCING AND/OR PREVENTING INTRA-ABDOMINAL ADHESIONS | December 2023 | February 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18530815 | PHARMACEUTICAL COMPOSITIONS OF MIFEPRISTONE | December 2023 | August 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18388898 | ORAL SOLID TABLET COMPRISING BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | November 2023 | September 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18380054 | SUSTAINED RELEASE FORMULATIONS OF DYSOXYLUM BINEFACTERUM | October 2023 | September 2024 | Allow | 11 | 0 | 1 | Yes | No |
| 18378949 | INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18477752 | EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION | September 2023 | December 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18205700 | COMPOSITIONS COMPRISING CYCLOSPORIN | June 2023 | September 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18162101 | FORMULATIONS FOR EXTENDING LIFESPAN AND HEALTHSPAN | January 2023 | October 2025 | Abandon | 33 | 3 | 0 | No | No |
| 18100396 | NEW PHARMACEUTICAL COMPOSITIONS | January 2023 | December 2023 | Allow | 10 | 2 | 0 | Yes | No |
| 18146510 | ORAL RIFAMYCIN SV COMPOSITIONS | December 2022 | March 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 17978383 | SYNERGISTIC DISINFECTANT COMPOSITIONS HAVING ENHANCED ANTIMICROBIAL EFFICACY AND STABILITY, AND METHODS OF USING THE SAME | November 2022 | August 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17967332 | LEVODOPA DOSING REGIMEN | October 2022 | March 2024 | Allow | 17 | 4 | 0 | Yes | No |
| 18045497 | SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES | October 2022 | January 2025 | Abandon | 27 | 0 | 1 | No | No |
| 17934234 | EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION | September 2022 | December 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17887866 | INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | August 2022 | July 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17758811 | DOSAGE FORM WITH SUSTAINED RELEASE MELATONIN PELLETS | July 2022 | November 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17858471 | DEXTROMETHORPHAN TRANSDERMAL DELIVERY DEVICE | July 2022 | January 2024 | Abandon | 19 | 2 | 0 | No | No |
| 17856817 | PELLET AND MULTI-UNIT PELLET SYSTEM (MUPS) | July 2022 | May 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17809288 | LOZENGE | June 2022 | June 2024 | Abandon | 24 | 3 | 0 | No | No |
| 17843669 | PHARMACEUTICAL COMPOSITIONS OF MIFEPRISTONE | June 2022 | September 2023 | Allow | 15 | 3 | 0 | Yes | No |
| 17833979 | GASTRO-RETENTIVE DRUG DELIVERY SYSTEM | June 2022 | October 2025 | Allow | 41 | 3 | 1 | Yes | No |
| 17660999 | MODIFIED RELEASE ORALLY ADMINISTERED AMINO ACID FORMULATIONS | April 2022 | June 2025 | Allow | 37 | 1 | 1 | No | No |
| 17769051 | ORAL FILM AND STICK JELLY FOR IMPROVING ABSORPTION IN THE ORAL MUCOSA, ANTIOXIDANT ACTIVITY, ANTI-INFLAMMATORY ACTIVITY, AND LIVER FUNCTION OF HUMANS AND COMPANION ANIMALS | April 2022 | October 2025 | Allow | 42 | 2 | 0 | No | No |
| 17767071 | Novel Dental Care and Cleansing Composition | April 2022 | June 2025 | Allow | 38 | 2 | 0 | No | No |
| 17714178 | SYNERGISTIC DISINFECTANT COMPOSITIONS HAVING ENHANCED ANTIMICROBIAL EFFICACY AND STABILITY, AND METHODS OF USING THE SAME | April 2022 | June 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17703626 | TREATMENT OF LONG HAULERS SYNDROME WITH NICLOSAMIDE | March 2022 | June 2023 | Abandon | 15 | 2 | 0 | No | Yes |
| 17762272 | AMORPHOUS EFINACONAZOLE SOLID DISPERSION | March 2022 | March 2024 | Allow | 24 | 1 | 1 | No | No |
| 17642043 | PROCESS FOR THE PREPARATION OF A NANOPARTICULATE ACTIVE INGREDIENT | March 2022 | April 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17652210 | LYCIUM BARBARUM LEAF POLYSACCHARIDE RICH IN GALACTURONIC ACID AND PREPARATION METHOD AND USE THEREOF | February 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17635441 | LARAZOTIDE FORMULATIONS | February 2022 | February 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17589963 | FINE BAMBOO POWDER AND PREPARATION METHOD THEREFOR AND USE THEREOF | February 2022 | August 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17562899 | Controlled Release Formulations and Methods of Targeted Drug Delivery within the Small Intestine Wall | December 2021 | September 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17560493 | EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION | December 2021 | June 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17558337 | LEVODOPA DOSING REGIMEN | December 2021 | December 2024 | Allow | 35 | 5 | 0 | Yes | No |
| 17553367 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | December 2021 | April 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17615422 | CANNABINOID FORMULATIONS | November 2021 | October 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17595352 | DOSING SYSTEM FOR CONTROLLED SUBSTANCES RELEASE BY MEANS OF DOSING MEMBRANES | November 2021 | January 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17609161 | AGRIMONY EXTRACT AS ANTI-POLLUTION AGENT | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17512139 | COMPOSITION AND METHODS OF TREATMENT | October 2021 | July 2024 | Allow | 33 | 3 | 0 | Yes | No |
| 17606928 | PELLET AND MULTI-UNIT PELLET SYSTEM (MUPS) | October 2021 | April 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17509965 | Formulations of 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, Taste-Modified Formulations, and Methods of Making and Using Same | October 2021 | January 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17509502 | TEXTILE YARN WITH ANTIVIRAL PROPERTIES, AND METHODS THEREOF | October 2021 | September 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17601463 | FORMULATIONS FOR TREATING PSORIASIS | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17441828 | PLANT PEPTIDES AND THEIR APPLICATIONS (II) | September 2021 | July 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17442016 | METHOD OF PRODUCTION OF A COMPOSITE OF YEAST-DERIVED BETA GLUCAN PARTICLE WITH INCORPORATED POORLY-WATER-SOLUBLE LOW-MOLECULAR-WEIGHT COMPOUND, PHARMACEUTICAL PREPARATION AND USE THEREOF | September 2021 | November 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17438802 | PHENPROCOUMON TTS | September 2021 | September 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17470096 | GRANULE, PREPARATION CONTAINING THE GRANULE, PRODUCTION METHOD OF THE GRANULE, AND PRODUCTION METHOD OF PREPARATION CONTAINING THE GRANULE | September 2021 | June 2025 | Allow | 45 | 4 | 1 | Yes | No |
| 17434754 | A Product and Process For A Room-Temperature Stable, Food-Grade, All-Natural, Vegan, And Phyto-Cannabinoid/Terpene/Flavonoid Colloidal Dispersion | August 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17387517 | LIQUID CLONIDINE EXTENDED RELEASE COMPOSITION | July 2021 | October 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17356120 | ORAL DOSAGE FORM OF TICAGRELOR AND PREPARATION METHOD THEREOF | June 2021 | March 2023 | Allow | 21 | 1 | 0 | Yes | No |
| 17303980 | PHARMACEUTICAL COMPOSITION COMPRISING PURPLE CORN EXTRACT FOR PREVENTION OR TREATMENT OF SKIN DISEASE | June 2021 | November 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17299893 | LONICERA JAPONICA FLOWER WATER EXTRACT-CONTAINING PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HELICOBACTER PYLORI INFECTION | June 2021 | May 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17311161 | USE OF COCCULUS HIRSUTUS EXTRACT FOR TREATING DENGUE | June 2021 | August 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17336166 | SYNERGISTIC MEDICINAL COMPOSITIONS FOR TREATING DYSFUNCTIONAL D-SERINE SIGNALING | June 2021 | April 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17333528 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | May 2021 | April 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17315519 | COMPOSITIONS AND METHODS FOR TREATMENT OF COVID-19 | May 2021 | December 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17308399 | EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION | May 2021 | July 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17302525 | COSMETIC COMPOSITION | May 2021 | November 2025 | Abandon | 55 | 5 | 0 | No | No |
| 17284574 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING SLEEP DISTURBANCE COMPRISING EXTRACT OF FRAXINUS SP. PLANT AS EFFECTIVE COMPONENT | April 2021 | February 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17226703 | ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER | April 2021 | January 2024 | Abandon | 33 | 3 | 0 | Yes | No |
| 17226671 | ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER | April 2021 | November 2024 | Allow | 43 | 5 | 0 | Yes | No |
| 17282142 | MOLECULAR COMPLEX ASSEMBLY PARTICLES COMPRISING BIS-R1,R2-DITHIOCARBAMATE-METAL COMPLEX AND A LIGAND, METHOD OF PREPARATION AND USE THEREOF | April 2021 | April 2025 | Allow | 48 | 4 | 1 | Yes | No |
| 17219811 | COMPOSITIONS AND METHODS FOR STYLING THE HAIR | March 2021 | October 2025 | Allow | 55 | 5 | 1 | Yes | No |
| 17217347 | MEDICAL IMPLANT | March 2021 | August 2023 | Allow | 29 | 2 | 0 | No | No |
| 17216165 | COMPOSITIONS COMPRISING CYCLOSPORIN | March 2021 | July 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17280530 | NONWOVEN FABRIC FOR SKIN CARE PRODUCTS, FACE MASK, AND CLEANSING SHEET | March 2021 | September 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17213501 | EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION | March 2021 | September 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17276272 | COMPOSITION COMPRISING CUDRANIA TRICUSPIDATE AS EFFECTIVE COMPONENT FOR ALLEVIATING, TREATING, OR PREVENTING MUSCULAR DISEASES, OR IMPROVING MUSCULE FUNCTIONS | March 2021 | December 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17272739 | EXTRACTS OF MORICANDIA FOR THE USE THEREOF IN THE PREVENTION AND TREATMENT OF METABOLIC DISEASES | March 2021 | December 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17185600 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | February 2021 | April 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17178456 | THERAPEUTIC AGENT NANOPARTICLES AND METHODS OF PREPARATION | February 2021 | April 2025 | Allow | 50 | 4 | 1 | No | No |
| 17174947 | TRANSDERMAL DELIVERY FORMULATION | February 2021 | July 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17169807 | METHOD FOR PRODUCING GRANULES CONTAINING A CORE PARTICLE, GRANULES CONTAINING A CORE PARTICLE, PHARMACEUTICAL COMPOSITION CONTAINING THE GRANULES CONTAINING THE CORE PARTICLE, AND PREPARATION CONTAINING THE PHARMACEUTICAL COMPOSITION | February 2021 | July 2025 | Allow | 53 | 5 | 0 | Yes | No |
| 17169120 | SOLID ORAL DOSAGE FORMS OF ESLICARBAZEPINE | February 2021 | April 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17166988 | SELF-EMULSIFYING DOSAGE FORMS OF ALLERGEN AND THEIR PREPARATION THEREOF | February 2021 | September 2023 | Abandon | 32 | 1 | 1 | No | No |
| 17250551 | THIN TABLET, THIN TABLET PRODUCING METHOD, AND THIN TABLET PRODUCING APPARATUS | February 2021 | June 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17163942 | FORMULATIONS FOR A TIGHT JUNCTION EFFECTOR | February 2021 | September 2022 | Abandon | 20 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANNAVAJJALA, LAKSHMI SARADA.
With a 31.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHANNAVAJJALA, LAKSHMI SARADA works in Art Unit 1611 and has examined 893 patent applications in our dataset. With an allowance rate of 39.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner CHANNAVAJJALA, LAKSHMI SARADA's allowance rate of 39.5% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHANNAVAJJALA, LAKSHMI SARADA receive 3.24 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CHANNAVAJJALA, LAKSHMI SARADA is 42 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +2.3% benefit to allowance rate for applications examined by CHANNAVAJJALA, LAKSHMI SARADA. This interview benefit is in the 22% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 11.6% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 21.9% of cases where such amendments are filed. This entry rate is in the 28% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 60.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 58.5% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 53.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 55.7% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.7% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.